Held Hostage by a Form: The Hidden Cost of Insurance Prior Authorization on Patient Health

Your physician has just made a decision. After reviewing your symptoms, your lab results, and your medical history, she has determined that a specific medication is the right course of treatment for you. She sends the prescription electronically to your pharmacy. You arrive to pick it up—and you are told it isn't ready. Not because it is out of stock. Not because of a clerical error. Because your insurance company has not yet decided whether it agrees with your doctor.

This is prior authorization (PA), a cost-management tool used by health insurers that requires prescribers to obtain approval before a patient's plan will cover certain medications. In theory, it exists to prevent unnecessary or excessively expensive prescribing. In practice, it has become one of the most consequential and least visible obstacles in American healthcare—a bureaucratic checkpoint that can delay access to critical therapies for days, weeks, or, in some cases, indefinitely.

What Prior Authorization Actually Is—and Why Insurers Use It

Prior authorization is a pre-approval requirement embedded in most commercial insurance plans, Medicare Part D, and many Medicaid programs. When a prescriber writes for a medication that appears on an insurer's PA list, the pharmacy's claim is automatically rejected at the point of sale. The prescriber must then submit clinical documentation—diagnosis codes, prior treatment history, lab values, specialist notes—demonstrating that the prescribed drug is medically necessary.

Insurers argue that PA reduces wasteful spending and steers patients toward equally effective, lower-cost alternatives. Pharmaceutical benefit managers (PBMs), who administer drug benefits on behalf of insurers, maintain that the process protects patients from unnecessary exposure to high-risk or experimental therapies.

Critics, including the American Medical Association, counter that PA has expanded far beyond its original intent. A 2023 AMA survey found that 94 percent of physicians reported that PA delays patient access to necessary care, and 33 percent said a patient in their practice had experienced a serious adverse event as a direct result of a coverage delay.

The Clock Starts When You Can Least Afford to Wait

For many conditions, the interval between a prescription being written and a PA being approved is not a minor inconvenience—it is a clinically meaningful gap. Consider several scenarios where timing is paramount.

Oncology medications. Certain targeted cancer therapies and immunotherapies require PA before dispensing. For a patient beginning a new treatment regimen, a two-week delay can correspond to continued disease progression during a window that may have been therapeutically critical.

Psychiatric medications. Antipsychotics, mood stabilizers, and certain antidepressants frequently trigger PA requirements. For a patient in acute psychological distress who has just been discharged from inpatient care, being unable to fill a newly prescribed stabilizer can dramatically increase the risk of relapse or readmission.

Insulin and diabetes management. Newer insulin formulations and GLP-1 receptor agonists are among the most frequently PA-flagged drug classes. Diabetic patients forced to revert to older, less effective insulin products during a coverage dispute may experience suboptimal glycemic control with real consequences for long-term complications.

Cardiovascular therapies. PCSK9 inhibitors—medications prescribed to patients at high cardiovascular risk who cannot adequately lower LDL cholesterol with statins alone—have among the highest PA denial rates of any drug class. Patients waiting for approval may remain at elevated risk for myocardial infarction or stroke during the delay.

Inside the Bottleneck: Why Approvals Take So Long

The PA process involves multiple parties: the prescriber's office, the pharmacy, the PBM, and the insurer. Each hand-off introduces the potential for delay. Prescribers' offices often receive PA requests via fax—yes, fax—and may lack dedicated staff to process them promptly. Insurers are legally permitted to take up to 72 hours for standard PA decisions under most state regulations, and up to 24 hours for urgent requests. Many take the full allotted time.

Pharmacy staff are frequently the first to inform patients that a PA is required, yet pharmacists themselves have limited ability to expedite the process. "We can flag it as urgent and reach out to the prescriber's office, but once it leaves our hands, we're waiting just like the patient," one community pharmacist in the Midwest explained. "The most frustrating calls are from patients who genuinely need the medication and don't understand why a decision their doctor already made has to be made again by someone who has never examined them."

Strategies to Expedite Your Prior Authorization

While the system is imperfect, patients are not powerless. The following approaches can meaningfully accelerate the process.

Request an expedited or urgent review. Federal regulations and most state laws require insurers to process urgent PA requests within 24 to 72 hours. Ask your prescriber to explicitly flag the request as urgent and to document the clinical rationale for why a delay poses a health risk.

Ask about a bridge supply. Some pharmacies, particularly those with established insurer relationships, can dispense a limited supply of a medication while a PA is pending. Manufacturers of certain specialty medications also offer patient assistance programs that can serve as a bridge during coverage disputes.

Request peer-to-peer review. Your physician has the right to speak directly with the insurer's medical reviewer—a process called peer-to-peer review. This conversation can often resolve a denial more quickly than additional paperwork, particularly when the prescribing physician can articulate the clinical urgency.

File an appeal immediately upon denial. If a PA is denied, do not wait. Insurers are required to provide written denial notices with instructions for appeal. An appeal filed by your physician with supporting clinical documentation succeeds more frequently than the initial submission, particularly when it includes peer-reviewed literature supporting the prescribed therapy.

Contact your state insurance commissioner. Every U.S. state has an insurance regulatory office that handles consumer complaints. A formal complaint can prompt the insurer to expedite review, especially when a patient's health is demonstrably at risk.

Leverage your pharmacist as an advocate. Your pharmacist can initiate contact with your prescriber's office to ensure the PA request was received and to identify any missing documentation that may be causing delay. This coordination step is often overlooked but can shave days off the process.

Legislative Momentum—But No Resolution Yet

Congress has taken notice of the PA problem. The Improving Seniors' Timely Access to Care Act, which passed the House unanimously in 2022, sought to standardize and streamline PA requirements within Medicare Advantage plans. While the bill stalled in the Senate, it reflected a growing bipartisan recognition that the current system imposes real clinical harm.

Several states have enacted their own PA reform laws, establishing maximum turnaround times, requiring gold-carding provisions (which exempt physicians with strong prescribing track records from routine PA requirements), and mandating continuity of care protections during insurance transitions. Patients should familiarize themselves with the specific protections available in their state.

What You Should Know Before Your Next Prescription

Prior authorization is not going away in the near term. Understanding how it works—and how to navigate it—is now a practical necessity for patients managing chronic or complex conditions. Before leaving any medical appointment where a new medication is prescribed, consider asking whether that drug is likely to require PA under your specific plan. If it does, ask your provider's office to initiate the request the same day.

The gap between a physician's clinical judgment and an insurer's administrative approval should not determine patient outcomes. Until systemic reform catches up to the problem, informed patients who advocate for themselves within the existing process are best positioned to close that gap.

PharmaciTical provides medication education and wellness resources for informational purposes. This content does not constitute medical or legal advice. Consult your healthcare provider and insurance representative for guidance specific to your situation.